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Abstract
Background
Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is used during nonmyeloablative and reduced-intensity
conditioning haematopoetic cell transplantation (HCT) to improve engraftment and reduce graft versus host disease (GVHD).
However, information about MPA pharmacokinetics is sparse in this context and its use is still empirical.
Objectives
To perform a pilot pharmacokinetic study and to develop maximum Bayesian estimators (MAP-BEs) for the estimation ofa posteriori 
MPA exposure in HCT.
Patients and methods
Fourteen patients given orally MMF 15 mg/kg 3 times daily were included. Two consecutive 8-hour PK profiles were performed the
same day respectively three days before and 4 days after the HCT. One 8-hour PK profile was performed on day 27 after
transplantation. For these 8-hours pharmacokinetic profiles, blood samples were collected pre-dose and 20, 40, 60, 90 min, 2, 4, 6 and
8 h post-dose after administration of the drug.
Using the iterative two-stage method (ITS), two different one-compartment open PK models with first-order elimination were
developed to describe the data: one with two gamma laws and one with three gamma laws to describe the absorption phase. For each
PK profile, the Akaike criterion was calculated to evaluate model fitting. On the basis of the population PK parameters, MAP-BEs
were developed for the estimation of MPA pharmacokinetics and area under the concentration-time curves (AUC ) at the different0-8h 
studied periods using a limited sampling strategy (LSS). These MAP-BEs were then validated using a data-splitting method.
Results
The ITS approach allowed the development of MAP-BEs based either on double-gamma  or triple-gamma  models, the combination“ ” “ ”
of which allowed correct estimation of MPA pharmacokinetics and AUC on the basis of a C20min-C90min-C240min sampling
schedule. The mean bias of the Bayesian reference (trapezoidal) AUCs was <5  with less than 16  of the patients withversus % %
absolute bias on AUC > 20 . Akaike criterion was systematically calculated for the choice of the most appropriate model fitting the%
data.
Conclusion
PK models and MAP-BEs for MMF when administered to HCT patients have been developed. In the studied population, they allowed
the estimation of MPA exposure based on three blood samples, which could be helpful in conducting clinical trials for the
optimization of MPA in reduced-intensity HCT. However, prior studies will be needed to validate them in larger populations.
MESH Keywords Adult ; Anti-Inflammatory Agents, Non-Steroidal ; pharmacokinetics ; Area Under Curve ; Bayes Theorem ; Drug Monitoring ; methods ; Female ; 
Hematopoietic Stem Cell Transplantation ; methods ; Humans ; Male ; Middle Aged ; Models, Theoretical ; Mycophenolic Acid ; administration & dosage ; analogs &
derivatives ; blood ; pharmacokinetics ; Pharmacokinetics ; Pilot Projects ; Prodrugs ; pharmacokinetics ; Young Adult
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Introduction
Mycophenolate mofetil (MMF) is a prodrug of mycophenolic acid (MPA) largely used as an immunosuppressive drug to prevent acute
rejection following solid organ transplantation , . MMF is also used in the prophylaxis and treatment of acute and chronic[1 2 ]
graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HCT), or to improve the engraftment in nonmyeloablative
and reduced-intensity conditioning HCT .[3 –15 ]
On the one hand, the therapeutic drug monitoring (TDM) of MMF when used in solid organ transplantation is debated  but could[16 ]
be recommended as it has been demonstrated that the control of exposure to MPA helps to maximize its immunosuppressive effects .[2 ]
More precisely, an area under the twelve-hour concentration-time curve (AUC ) of MPA between 30 and 60 mg.h/L is recommended0-12 
for at least the first six months post-renal or heart transplantation, when MMF is used in combination with cyclosporine and steroids , [1 2 ]
. Bayesian estimators, based on pharmacokinetic models and using sparse individual data have been developed to estimate the dose
providing a target AUC value for each patient , . Some of these Bayesian estimators, derived from PK models built from large[17 18 ]
populations of transplanted patients, have been successfully used in a prospective concentration-controlled  clinical trial using a limited“ ”
sampling strategy (20 min, 1 h, 3 h) . These tools are also routinely used by transplantation centres via an expert system available on a[19 ]
website ( ) .https://pharmaco.chu-limoges.fr/abis.htm [20 ]
On the other hand, very little information is available about the TDM of MMF when used in HCT patients. The previous
pharmacokinetic studies have reported a wide interpatient variability with a mean total MPA exposure below that recommended in solid
organ transplantation , , , . Interestingly, mean dose-normalized MPA AUC values observed in HCT patients are almost 50[3 5 7 –9 14 ] %
lower than in renal transplant patients , . These observations advocate for MMF administration instead of as in solid organ[7 14 ] tid bid 
transplantation , . This also implies dose adjustments in HCT patients, but also strongly suggests that the pharmacokinetic[10 21 ]
parameters and their associated tools developed for solid organ transplant recipients would not be suitable for HCT. Furthermore, a recent
study underlines the interest of TDM of MPA in terms of reduction of inter-patient variability .[22 ]
This pilot study aimed at modelling MPA pharmacokinetics and developing maximum Bayesian estimators (MAP-BEs)a posteriori 
for the estimation of MPA exposure in reduced-intensity HCT patients given MMF as part of their immunosuppressive regimen.
Patients and methods
Patients
Fourteen patients were enrolled in the study. The inclusion criteria were: patient likely to receive a reduced-intensity HCT as
determined by the French Haematological Society, age ranging from 18 to 70 years, signing of informed consent, absence of intercurrent
disease which could interfere with the short term survival of the patient or graft. Non inclusion criteria were hypersensitivity to MPA,
patients who present contraindications to MPA, patients with severe gastro-intestinal disorders, drug addictions or psychiatric disorders
which mean they might not be able to understand the protocol. This clinical trial was designed in accordance with the legal requirements
and approved by a local ethics committee.
The reduced-intensity regimen was a combination of fludarabine and melphalan (in 8 cases), with total body irradiation (2 Gy in 2
cases) or with both cyclophosphamide and total body irradiation (2 Gy in 4 cases. The immunosuppressive regimen for the prevention of
GVHD was a combination of cyclosporine administered orally twice daily (start dose: 5mg/kg/day; targeted through concentration: 250
ng/mL) and MMF administered at the dose of 15 mg/kg three times daily. However, because of the galenic formulation of MMF (tablets of
500 and capsules of 250 mg), the actual dose administered was rounded off 1g of MMF . The two treatments were started 3 days beforetid 
the HCT.
The supportive care medication was as previously described . Briefly, it consisted in bacterial prophylaxis using[23 ]
phenoxymethylpenicilline (3 MU/day) or spiramycine (3 MU/day). Valacyclovir p.o. was administered to prevent CMV prophylaxis: 500
mg twice daily if donor and recipient was serologically CMV negative; 1g 3 daily when donor and/or recipient was CMV positive. Oral×
itraconazole (400 mg daily) or posaconazole (200 mg tid) were administered if fungal prophylaxis was needed.
Pharmacokinetic profiles
Three profiles were performed during the first month of HCT: one at the beginning of the treatment three days before the HCT and one
7 (  1) days later, i.e. 4 days after HCT. Finally a PK profile was collected after the morning on day 30 (  5) after the first PK profile. The± ±
two first PK profiles correspond with a two 8-hour PK profiles performed consecutively at the initiation of the MMF treatment. The
sequence of sampling was: pre-dose, 20, 40 and 60 minutes after the first administration in the morning, thereafter 2, 4, 6 and 8 hours.
Then samplings were performed at 20, 40 and 60 minutes and 2, 4, 6 and 8 hours after the administration of the second dose of MMF.
Finally, the last PK profile corresponds with a 8-hour PK profile collected after the morning on day 30.
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Assay
The measurement of total MPA was performed using an HPLC method with UV detection derived from . Briefly, a mixture of 1[24 ]
mL whole blood and 4 g of internal standard (thiopental) were acidified with chlorhydric acid and extracted with 4 mL ofμ
dichloromethane. The organic fraction was then evaporated to dryness under a stream of nitrogen. The drug residue was reconstituted with
the elution solvent (NaH PO buffer/acetonitrile (58/42 v/v) at pH  2.7). Thirty L of sample were injected into the HPLC system with a2 4 = μ
X-Terra column and precolumn (Waters, Saint Quentin en Yvelines, France) and with a UV detection at 254 nm. This method exhibits a
lower limit of quantification of 0.1 mg/L and a coefficient of variation of 6.0  for interday accuracy at the 1 mg/L concentration.%
PK modelling
The pharmacokinetic profiles were described by one-compartment open models with first-order elimination combined with a Gamma
model of absorption with either two or three parallel absorption routes. These PK models were previously published to describe PK
profiles of MPA in renal transplant patients ,  and in patients suffering from lupus . Briefly, in these models, the absorption rate[17 18 ] [25 ]
at time t was described by a sum of Gamma distributions:
with:
where F is the bioavailability coefficient, D is the administered dose, fi represents the absorption rate through the i-th route
(normalized by FD),  is the Gamma function, (a , b ) the parameters of the Gamma distributions, r is the fraction of drug absorbedΓ i i i 
through the i-th route. No independent determination of the bioavailability factor F was possible, since no intravenous data was available
for these patients.
The disposition kinetics, i. e. the impulse response I(t) of the system, was described by a one-compartment model, according to the
equation:
Where I(t) is the drug concentration at time t following an intravenous bolus of a unit dose D A is the initial concentration following0, IV 
an intravenous bolus administration of a unit dose, and  is the apparent elimination rate following the same intravenous bolusκ
administration.
The convolution product of the absorption rate and disposition function was computed analytically as previously described , :[26 27 ]
Where C is the concentration at time t, C the trough concentration, a and b the parameters of the Gamma distributions, r is the0 i i i 
fraction of drug absorbed through the i-th route, and P denotes the incomplete Gamma function:
Where is the exponent of the incomplete Gamma function, is the independent variable (argument of the incomplete Gamman x 
function) and z is the integration variable.
Bayesian estimation of individual pharmacokinetic parameters
The individual parameters (vector ) for each patient were determined by minimizing the following objective function: θ
Where the symbols have the following meanings:
: objective function corresponding to the Bayesian posterior distribution Φ
n: number of experimental points
C : concentration measured at time ti i
Clin Pharmacokinet . Author manuscript
Page /4 12
f(t , ): concentration computed at time ti  θ i
v : variance of measured concentrationi 
: vector of model parameters θ
: mean parameter values in the reference population μ
: variance-covariance matrix of parameters in the reference population Ω
the symbol denotes matrix transpositionT 
The variance-covariance matrix of the posterior distribution of the parameter estimates for each patient was computed by theV 
classical approximation:
Where denotes the Jacobian matrix (J  f(t , )/  ) and W the diagonal matrix of weights (W  1/v ). The determinant of VJ ij = ∂ i  θ ∂ θj ii = i 
(detV) was used as a measure of the precision of the determined parameters with which parameters were determined (the lower the
determinant, the higher the precision).
Population pharmacokinetics
The population pharmacokinetic parameters for were determined by the iterative two-stage (ITS) method , , using our own[28 29 ]
program. At each iteration of the method, the following two steps were performed:
Individual estimates and V (k  1..N) for the N patients were obtained by Bayesian estimation as described above θ k k =
New estimates of the population mean vector and population variance-covariance matrix were computed by: μ  Ω
The interindividual variability of the pharmacokinetic parameters was assessed by computing the medians and 50  dispersion factors%
(DF50). DF50 is defined as (Q75 - Q25)/1.32, whereQ75 and Q25 are the 25  and 75  quartiles, respectively, and 1.32 represents the% %
width of the interval covering 50  of the observations in the case of a normal distribution. DF50 is equal to the standard deviation for%
normally distributed parameters and provides a reasonable estimate of the dispersion of a non-Gaussian distribution .[26 ]
The calibration experiments showed that the standard deviation Si of a measured concentration Ci could be expressed as a polynomial
function Si  0.02  0.033 Ci, where Ci and Si are in mg/L. Si was used as concentration weighting factor.= +
For each PK profile, the two PK model were applied and the best one was selected based on the lowest Akaike Information Criterion [
, calculated as follows:30 ]
Where is the value of the objective function at minimum, and p the number of parameters in the model. Φ min 
Determination of a Limited Sampling Strategy for the estimation of the AUC
For each pre- and post-transplantation period, limited sampling strategies were tested for Bayesian forecasting with the aim of
estimating the AUC . As previously done with renal , , combinations of a maximum of three sampling times within 4 hours0-8h [17 18 ]
post-dose were tested for Bayesian forecasting. Indeed, such a sampling scheme seemed to be a good compromise between the precision of
parameter estimates and a possible implementation in clinical practice.
The D-optimality criterion  applied to Bayesian estimation was used to compare these candidate LSS as follows:[30 ]
For given sampling times t , t ,  the corresponding concentrations C , C , were computed by , using the population mean1 2 … 1 2 … eq. (4) 
vector . μ
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The variance-covariance matrix was then computed with . The sampling times giving the lowest value of det were selected aseq. (7) V 
the best  sampling times.‘ ’
The Bayesian estimators corresponding to each period were evaluated separately, by comparison of observed and estimated AUC0 8 h –
estimates obtained using the selected limited-sampling strategy and BE and the linear trapezoidal rule applied to the full profiles (reference
values). Additionally bias and Root Mean Squared Error (RMSE) were computed according to Sheiner and Beal s recommendations .’ [31 ]
In a second step, a data-splitting procedure was performed to validate these MAP-BEs, in accordance with previous reports , .[32 33 ]
For each period, patients were randomly divided into subsets containing approximately 80  of the patients. To test the robustness of the%
model, new population parameters were obtained in each 80  subset  and were then compared with those resulting from the entire“ % ”
population. To test the predictive performance of the MAP-BEs, the parameter estimates from each of the subsets were used to estimate
the PK parameters and the AUCs of the remaining 20  patients. The predicted AUCs were compared with those obtained using the linear%
trapezoidal rule by means of the mean bias and RMSE.
Results
The characteristics of the patients are summarized in . All PK profiles could be achieved except in two cases: one on D30 dueTable 1 
to missing data and one on D7 because the MMF treatment was administered intravenously after the development of an oral mucositis.
The MMF dose was of 1000 mg for all the patients for the first PK profile. On D7, the MMF dose was of 1000 mg except in threetid tid 
patients (two at 750 mg and 1 at 500 mg ). The reducing of these doses was maintained for the last PK period (D30) and extended totid tid 
one additional patient (750 mg ). On D30, the MMF dose was increased for one patient (1500 mg ).tid tid 
The observed concentration-time profiles obtained before transplantation and on D7 and D30 are presented in . Whatever thefigure 1 
period, these individual profiles were satisfactorily described using a one-compartment model with either a double or a triple gamma
absorption. Some typical examples illustrating the good-of-fit are given on . The performance of the models are depicted in table xfigure 2 
(published as only online supplementary material). Interestingly, for each parameter of the models, the precision of the estimation gave
satisfactory results (from 5.2 to 32.6 , depending on both period or PK model). Also, the medians were very close to the means, the DF50%
values very close to the standard deviations and the Kolmogorov-Smirnov test did not find significant deviations from the normal
distribution, as required. Thus, population PK parameters of the two models were used as priors for Bayesian estimation. The Akaike
criterion was pertinent in discriminating which model best fitted each patient s data. A typical example of the difference in data modelling’
using a double gamma  or a triple gamma  model and the corresponding Akaike criterion values is presented in .“ ” “ ” figure 3 
With respect to both the AUC estimation performance and the D-optimality criterion, the combination of sampling times at 20min,0 8 h –
90min and 240min post-dose was found to be the best compromise when considering all the pre- and post-transplantation periods. Figure 3
gives four typical examples of MPA PK profiles estimated using Bayesian fitting. The predictive performance of the different MAP-BEs is
summarized in . For each period, mean bias between calculated  and trapezoidal  AUC was less than 2.5  and the percentage oftable 2 “ ” “ ” %
patients with a bias greater than 20  was less than 16 . Precisely, on D7, 2 out of 12 patients were estimated with a bias of 23  and 28% % − % +
, respectively. These 2 last cases are presented in .% figure 3 
The MAP-BEs were then validated using a data-splitting strategy. After randomly dividing the patients of the full dataset into subsets
containing approximately 20  of the patients, the individual PK parameters of each patient in the remaining 80  subset  was obtained% “ % ”
using the final model developed from the whole dataset. In this first step the mean parameter estimates obtained in each 80  subset  were“ % ”
not statistically different from those resulting from the entire dataset, which showed the robustness of the model. The mean  SD of the±
parameter estimates from each 80  subset  were then used to predict the individual AUC values in the remaining 20  subset . In this“ % ” “ % ”
second step, the mean bias between individual AUC values estimated using the 20min-90min-240min sampling schedule and the
trapezoidal rule was less than 9 . Whatever the period, less than 16  of the AUC were estimated with a relative difference of more than% %
20  (2 out of 14 patients on day 7 and 2 out of 14 patients on the 1 administration).% st 
Discussion
We report the development of pharmacokinetic models that adequately describe full pharmacokinetic profiles of MPA obtained in
patients receiving MMF three times daily in the context of a reduced-intensity HCT. We also developed Bayesian estimators allowing the
determination of the MPA AUC on the basis of a three-point limited sampling strategy within the first 4 hours post-dose.0-8h 
Patients enrolled in the present study provided full MPA PK profiles before transplantation, then on D4 and D27 post-transplantation.
When looking at the raw data, we observed that the patients usually exhibited profiles with more than one peak. For this reason, we
decided to develop a model able to describe a secondary peak, similar to that previously reported for solid organ transplantation , .[17 18 ]
Clin Pharmacokinet . Author manuscript
Page /6 12
Due to the complexity of some profiles, a model allowing the description of an additional peak was also constructed. As this leads to an
increase in the number of independent estimated parameters, we proposed the use of the Akaike criterion (AIC) to prevent overfitting and
to determine the model that best explains each individual data with a minimum of PK parameters.
Indeed, AIC reflects not only the goodness of fit, but also includes a penalty which is an increasing function of the number of
estimated parameters. For each patient, Bayesian fitting was thus automatically performed using the two PK models, and only the results
corresponding to the lowest AIC value were considered and reported. Of note, such a strategy is routinely performed on the ISBA website
( ) where PK modelling is performed systematically using a one- and a two-gamma absorptionhttps://pharmaco.chu-limoges.fr/abis.htm 
model, and the AIC criterion is used to choose which results will be used for dose adjustment of MMF when used in solid organ
transplantation.
Only a few pharmacokinetic studies have been published describing the MPA PK parameters or exposures when MMF is administered
to HCT patients in prevention of GVHD, especially after reduced-intensity regimen , , , . These studies have reported that the[7 8 12 34 ]
mean exposure to MPA (in its total or unbound form) is significantly lower than that observed in solid organ transplantation. The causes of
this phenomenon are still controversial. However, to the best of our knowledge, only two MPA PK studies have been performed in HCT
patients with the aim of building a tool for improving the therapeutic drug monitoring of MMF , . Using a noncompartmental[35 36 ]
approach, Ng . have developed different equations derived from multilinear regression models allowing the estimation of total oret al 
unbound MPA AUC in HCT patients given MMF orally or intravenously. In the second study, Huang aimed at developing a PKet al 
model able to estimate unbound MPA concentrations from unbound MPA concentrations. However, using their multilinear regression
equation failed to provide a satisfactory prediction for clinical assessment. In the present study, we developed Bayesian estimators able to
accurately estimate AUC as well as the relevant pharmacokinetic parameters or exposure indices to MPA using three sampling times. As
compared to algorithms using multilinear regression models, the combination of the patient s information and the PK model leads to an’
accurate estimation of unusual  pharmacokinetic profiles and is less sensitive to imprecision in sampling time.“ ”
A data-splitting strategy was performed here to validate both the PK models and MAPB-BEs. This approach was recommended by the
U.S. Department of Health and Human Services of the U.S. Food and Drug Administration (FDA) . Precisely, although external[37 ]
validation is the gold standard  for testing the accuracy of a population model for predictive purposes in clinical practice, this method is“ ”
hardly usable when the population studied is too small to be divided into a building and a validation group. This was the case in the present
study. In fact, the diminution of the building group s size leads to a decrease in the accuracy of the parameters and variability estimates.’
However, an external validation of the developed MAP-BEs is required before they can either be proposed to the physicians in charge of
HCT patients through the ISBA website, or used to conduct a concentration-controlled trial such as the one which recently showed the
significant improvement for renal transplant patients using such a strategy  and a couple of other on-going studies in liver[19 ]
transplantation.
Conclusion
Currently mycophenolate mofetil is widely used in solid organ transplantation. Numerous pharmacokinetic studies and some “
controlled-concentration  trials have led, in the last few years, to a significant improvement of its monitoring in these patients. MMF is”
also prescribed in HCT, but prescribed doses are still empirical as target exposure indices still have to be defined. In this study, we
developed PK that satisfactory described MPA absorption profiles when given to HCT patients. Additionally, Bayesian estimators able to
determine the AUC on the basis of a routinely usable limited sampling strategy. However, further studies are needed to validate these tools
in independent groups of patients.
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Figure 1
Observed concentration-time profiles of mycophenolic acid in patients given mycophenolate mofetil every 8 hours in non myeloablative
haematopoietic cell transplantation. (a) before transplantation; (b) 4 days after the initiation of MMF treatment; (c) 27 days after the initiation
of MMF treatment.
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Figure 2
Individual mycophenolic acid plasma concentration versus time curves at different periods of the study fitted using the developed PK models.
(a): after the first administration of MMF; (b): 4 days after the HCT; (c): 27 days after the HCT
Figure 3
Modeling of the concentration-time profile of mycophenolic acid obtained from a patient given mycophenolate mofetil every 8 hours on day 7
after the initiation of MMF treatment, using either a triple gamma  model ( ) or a double gamma  model (_). ( ) represent the observed“ ” _ “ ” □
concentrations. AIC values where 20 and 32 for a triple gamma  and a double gamma  model, respectively“ ” “ ”
Figure 4
Bayesian fitting of four MPA pharmacokinetic profiles using a limited sampling strategy (t20min; t90min; t240min) in patients receiving
MMF every 8 hours after an HCT.
Clin Pharmacokinet . Author manuscript
Page /10 12
Table 1
Patient characteristics at the time of the first pharmacokinetics
Patients Characteristics Number of patients or median value (range)
Age (years) 50.5 (20  60)–
Ratio female/male 6/8
Diagnosis
 Hodgkin lymphoma stage IV 1
 Myelodysplastic syndrome - refractory anemia with excess of blasts 1
 Chronic myeloid leukemia 1
 Acute myeloid leukemia (whatever the type) 7
 Chronic lymphoblastic leukemia 1
 agnogenic myeloid metaplasia 1
Table 2
Parameters of the different one-compartment open models with first-order elimination combined with a Gamma model of absorption with either two or three parallel absorption routes. 3 gamma laws.
Estimation ( ) represents the mean is the considered sub-group.%
Parameter
1 administrationst 
3 gamma laws
n  14= C0 a1 b1 a2 b2 a3 b3 r1 r2 F A_IV*
Mean 0.013 28.054 56.930 51.157 43.887 38.284 8.576 0.277 0.511 1.704
SD 0.018 8.423 13.474 15.572 6.736 15.202 3.228 0.150 0.223 0.851
Min 0.003 17.893 38.413 18.629 35.783 8.609 3.525 0.011 0.139 0.799
Max 0.073 51.524 75.000 74.771 55.571 61.549 13.719 0.558 0.915 3.363
estimation ( )% 15.3 21.8 21.4 17.0 16.8 22.0 21.1 21.4 10.2 7.9
2 gamma laws
n  14= C0 a1 b1 a2 b2 r F A_IV* Alpha
Mean 0.014 22.280 38.991 35.409 22.829 0.430 1.450 0.856
SD 0.005 10.310 11.498 10.009 8.199 0.282 0.808 0.337
Min 0.010 9.843 9.665 22.591 7.272 0.010 0.326 0.182
Max 0.026 46.537 50.000 50.000 35.990 1.000 3.057 1.627
estimation ( )% 10.7 27.4 28.0 25.6 27.7 16.1 6.6 5.1
2 administrationnd 
3 gamma laws
n 14= C0 a1 b1 a2 b2 a3 b3 r1 r2 F A_IV*
Mean 0.053 27.376 53.236 44.184 30.205 44.285 14.739 0.293 0.461 1.700
SD 0.037 14.206 13.356 7.935 10.495 18.293 4.414 0.181 0.115 0.612
Min 0.002 10.290 26.712 29.258 12.028 7.553 8.539 0.010 0.266 0.887
Max 0.120 61.550 74.991 55.238 45.385 74.976 24.838 0.535 0.608 2.951
estimation ( )% 11.1 28.3 25.5 18.4 17.9 25.0 20.8 20.3 21.4 13.9
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2 gamma laws
n  14= C0 a1 b1 a2 b2 r F A_IV* Alpha
Mean 0.056 26.124 37.081 33.192 19.462 0.502 1.897 1.582
SD 0.037 12.211 9.330 13.502 8.703 0.288 1.014 0.954
Min 0.010 10.458 21.105 9.847 3.071 0.010 0.400 0.274
Max 0.120 49.828 50.000 49.999 34.870 1.000 4.233 3.609
estimation ( )% 5.2 19.2 17.6 24.6 25.8 11.9 11.0 9.8
4 days after HCT
3 gamma laws
n  13= C0 a1 b1 a2 b2 a3 b3 r1 r2 F A_IV*
Mean 0.087 30.478 55.532 40.862 31.617 46.226 14.321 0.229 0.375 2.264
SD 0.098 7.468 11.380 9.919 7.452 12.421 4.084 0.125 0.118 0.727
Min 0.021 16.411 32.574 21.406 14.999 18.313 5.416 0.033 0.103 0.843
Max 0.414 44.680 75.000 59.891 44.362 68.189 22.779 0.483 0.580 4.189
estimation ( )% 4.5 20.0 22.5 19.6 20.0 20.5 20.1 15.4 15.8 17.1
2 gamma laws
n  13= C0 a1 b1 a2 b2 r F A_IV* Alpha
Mean 0.089 20.780 33.694 33.914 17.332 0.481 1.768 1.242
SD 0.087 6.804 13.136 10.766 6.297 0.256 0.968 0.501
Min 0.019 9.713 12.880 13.883 5.771 0.067 0.374 0.340
Max 0.390 32.030 50.000 50.000 34.355 1.000 4.552 2.186
estimation ( )% 4.4 23.0 25.8 26.1 27.8 14.8 13.7 12.1
27 days after HCT
3 gamma laws
n  13= C0 a1 b1 a2 b2 a3 b3 r1 r2 F A_IV*
Mean 0.0873 32.958 62.467 38.9 29.932 43.49 18.46 0.2478 0.222 2.6028
SD 0.0276 7.784 7.6511 8.8215 8.2111 14.719 2.7245 0.1352 0.109 1.0434
min 0.0556 19.049 50.559 26.763 23.294 16.66 14.12 0.0118 0.063 1.0866
max 0.1115 44.872 75 57.247 38.734 64.809 22.554 0.4426 0.412 4.1407
estimation ( )% 11.8 16.0 16.1 15.9 22.0 19.9 15.0 29.7 32.6 28.3
2 gamma laws
n  13= C0 a1 b1 a2 b2 r F A_IV* Alpha
mean 0.074 15.410 21.477 31.423 16.071 0.341 3.042 1.762
SD 0.022 3.796 4.553 8.571 2.628 0.172 1.925 0.819
min 0.047 8.779 13.629 19.625 12.164 0.031 0.577 0.821
max 0.119 24.147 26.726 45.680 20.742 0.611 6.644 3.254
estimation ( )% 9.6 21.5 20.1 17.2 14.2 29.7 23.1 23.6
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Table 2
Performance of the PK models and Bayesian estimators
Model
Before transplantation After transplantation
1 administrationst 2 administrationnd D4 D27
Bias between AUC and AUCmod trap −0.014  0.068± −0.010  0.049± −0.035  0.049± 0.022  0.057±
(m  sd) range± [ ] [−0.082; 0.156] [−0.081; 0.086] [−0.108; 0.058] [−0.092; 0.136]
RMSE 0.067 0.048 0.058 0.040
Bayesian estimators based on a t20min t90min  t240min sampling– –
schedule
Before transplantation After transplantation
1 administrationst 2 administrationnd D4 D27
Bias between AUC and AUCmod trap −0.008  0.068± −0.060  0.081± −0.025  0.121± 0.022  0.06±
(m  sd) range± [ ] [−0.179; 0.195] [−0.153; 0.078] [−0.230; 0.281] [−0.092; 0.136]
RMSE 0.010 0.098 0.112 0.040
